Blauvelt, A., Langley, R., Lebwohl, M., Strober, B., Warren, R., Puig, L., . . . Thaçi, D. (2025). Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. MOSBY-ELSEVIER.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
Blauvelt, A., et al. Bimekizumab Durability of Efficacy Through 196 Weeks and Safety Through 4 Years in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Trial. MOSBY-ELSEVIER, 2025.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
Blauvelt, A., et al. Bimekizumab Durability of Efficacy Through 196 Weeks and Safety Through 4 Years in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Trial. MOSBY-ELSEVIER, 2025.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.